International Assets Investment Management LLC Makes New Investment in CVRx, Inc. (NASDAQ:CVRX)

International Assets Investment Management LLC acquired a new position in CVRx, Inc. (NASDAQ:CVRX - Free Report) in the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 38,324 shares of the company's stock, valued at approximately $338,000. International Assets Investment Management LLC owned approximately 0.18% of CVRx at the end of the most recent quarter.

Other institutional investors have also recently bought and sold shares of the company. Johnson & Johnson increased its stake in shares of CVRx by 17.4% in the 1st quarter. Johnson & Johnson now owns 4,103,430 shares of the company's stock valued at $74,723,000 after buying an additional 607,855 shares during the period. Vanguard Group Inc. increased its position in CVRx by 5.6% during the first quarter. Vanguard Group Inc. now owns 594,312 shares of the company's stock worth $10,822,000 after buying an additional 31,720 shares during the last quarter. Silvercrest Asset Management Group LLC boosted its holdings in shares of CVRx by 70.7% during the first quarter. Silvercrest Asset Management Group LLC now owns 253,968 shares of the company's stock worth $4,625,000 after acquiring an additional 105,198 shares during the period. Squarepoint Ops LLC increased its holdings in shares of CVRx by 26.3% during the second quarter. Squarepoint Ops LLC now owns 91,999 shares of the company's stock worth $1,103,000 after purchasing an additional 19,165 shares during the period. Finally, Marshall Wace LLP bought a new position in CVRx in the second quarter valued at approximately $495,000. Institutional investors own 75.27% of the company's stock.

CVRx Stock Up 0.6 %

NASDAQ:CVRX traded up $0.10 during mid-day trading on Thursday, hitting $15.52. The company's stock had a trading volume of 257,120 shares, compared to its average volume of 278,839. The company has a debt-to-equity ratio of 0.76, a current ratio of 11.32 and a quick ratio of 8.85. The business's fifty day moving average is $9.48 and its two-hundred day moving average is $9.54. CVRx, Inc. has a 1 year low of $6.40 and a 1 year high of $33.13.

CVRx (NASDAQ:CVRX - Get Free Report) last posted its quarterly earnings results on Tuesday, October 29th. The company reported ($0.57) EPS for the quarter, missing the consensus estimate of ($0.45) by ($0.12). The firm had revenue of $13.37 million for the quarter, compared to analyst estimates of $13.28 million. CVRx had a negative return on equity of 89.06% and a negative net margin of 123.75%. During the same quarter last year, the firm earned ($0.43) EPS. As a group, sell-side analysts anticipate that CVRx, Inc. will post -2.62 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of research firms have weighed in on CVRX. Piper Sandler reissued an "overweight" rating and set a $16.00 target price (up previously from $13.00) on shares of CVRx in a research report on Wednesday, October 30th. Lake Street Capital increased their target price on CVRx from $12.00 to $15.00 and gave the stock a "buy" rating in a research report on Wednesday, October 30th. Craig Hallum lifted their price target on CVRx from $15.00 to $20.00 and gave the company a "buy" rating in a research report on Monday. Canaccord Genuity Group upped their price objective on shares of CVRx from $15.00 to $17.00 and gave the company a "buy" rating in a research note on Wednesday, October 30th. Finally, Cantor Fitzgerald reissued an "overweight" rating and issued a $14.00 target price on shares of CVRx in a research note on Wednesday, October 23rd. Two equities research analysts have rated the stock with a hold rating and five have given a buy rating to the stock. According to MarketBeat.com, CVRx has a consensus rating of "Moderate Buy" and an average price target of $15.83.

About CVRx

CVRx, Inc, a commercial-stage medical device company, focuses on developing, manufacturing, and commercializing neuromodulation solutions for patients with cardiovascular diseases. The company offers Barostim, a neuromodulation device indicated to improve symptoms for patients with heart failure with reduced ejection fraction or systolic heart failure.